Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Capital Expenditures (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Capital Expenditures data on record, last reported at $86000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 330.0% year-over-year to $86000.0; the TTM value through Dec 2025 reached $138000.0, down 12.1%, while the annual FY2025 figure was $138000.0, 12.1% down from the prior year.
  • Capital Expenditures reached $86000.0 in Q4 2025 per AMLX's latest filing, up from $24000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.1 million in Q2 2022 and bottomed at -$19000.0 in Q3 2024.
  • Average Capital Expenditures over 5 years is $232368.4, with a median of $153000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: soared 2342.86% in 2022, then tumbled 105.32% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $186000.0 in 2021, then skyrocketed by 233.33% to $620000.0 in 2022, then tumbled by 42.58% to $356000.0 in 2023, then tumbled by 94.38% to $20000.0 in 2024, then skyrocketed by 330.0% to $86000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $86000.0 in Q4 2025, $24000.0 in Q3 2025, and $17000.0 in Q2 2025.